ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis

Bone, Henry G; Cosman, Felicia; Miller, Paul D; Williams, Gregory C; Hattersley, Gary; Hu, Ming-yi; Fitzpatrick, Lorraine A; Mitlak, Bruce; Papapoulos, Socrates; Rizzoli, René; Dore, Robin K; Bilezikian, John P; Saag, Kenneth G

doi:10.1210/jc.2018-00163

Scientific article

English

ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis

ContributorsBone, Henry G; Cosman, Felicia; Miller, Paul D; Williams, Gregory C; Hattersley, Gary; Hu, Ming-yi; Fitzpatrick, Lorraine A; Mitlak, Bruce; Papapoulos, Socrates; Rizzoli, René; Dore, Robin K; Bilezikian, John P; Saag, Kenneth G

Published inJournal of Clinical Endocrinology and Metabolism, vol. 103, no. 8, p. 2949-2957

Publication date2018

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

Génétique des ostéoporoses (544)

Citation (ISO format)

BONE, Henry G et al. ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. In: Journal of Clinical Endocrinology and Metabolism, 2018, vol. 103, n° 8, p. 2949–2957. doi: 10.1210/jc.2018-00163

Article (Published version)

Identifiers

PID : unige:111093
DOI : 10.1210/jc.2018-00163

Additional URL for this publicationhttps://academic.oup.com/jcem/article/103/8/2949/5001732

Journal ISSN0021-972X

357views

0downloads

Creation21/09/2018 11:26:00

First validation21/09/2018 11:26:00

Update time15/03/2023 13:51:30

Status update15/03/2023 13:51:29

Last indexation31/10/2024 11:50:04

Archive ouverte UNIGE

ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis

Technical informations